The CDIATM Creatine Kinase MB Immunofluorescence Test Cassette is designed for quantitative determination of creatine kinase MB in human serum, whole blood or plasma.
The test uses an anti-human CK-MB monoclonal antibody conjugated with fluorescence latex and another anti-human CK-MB monoclonal antibody coated on the test line. After the sample has been applied to the test strip, the fluorescence latex-labelled anti-human CK-MB monoclonal antibody binds with the CK-MB in sample and forms a marked antigen-antibody complex. This complex moves to the test card detection zone by capillary action. Then marked antigen-antibody complex is captured on the test line by the anti-human CK-MB monoclonal antibody. The fluorescence intensity of the test line increases in proportion to the amount of CK-MB in sample. Then insert test card into the Fluorescent Immunoassay Analyzer FIA7100, the concentration of CK-MB in sample will be determined and displayed on the screen.
Creatine kinase is a dimer existing in three isoenzymic forms, depending on the particular combination of its subunits: BB(brain type);MM(skeletal type); and MB(hybrid type). Creatine kinase-MB isoenzyme is released into circulation later than myoglubin, reaching abnormal levels within 4 to 6 hours after onset of symptoms. It reaches its highest level after about 18 to 24 hours, and returns to normal in about 2 to 3 days. CK-MB is widely recognized as the traditional marker for the diagnosis of acute myocardial infarction (AMI). This kit is intended to use in quantitative detection of CK-MB content in human serum, plasma or whole blood.